Brilliant Violet 605™ beta test results



Comparison of Cytokine Expression on CD154+/CD8+ and CD154+/CD8- cells

11-0011-00

Data provided by Morgan Reuter and Michael Betts, University of Pennsylvania

Toll-Free Tel: (US & Canada): 1.877.BIOLEGEND (246.5343) Tel: 858.768.5800


biolegend.com

Cat. No.	Description	Clone
301039	Brilliant Violet 605™ anti-human CD8a	RPA-T8
310823	Brilliant Violet 421™ anti-human CD154	24-31

Brilliant Stability for Intracellular Staining

CD154 (CD40L) is upregulated in activated cells, where it interacts with CD40 to induce B-cell activation, cytokine production and thus, fate determination. For this experiment, T cell activation is determined by expression of IL-2 and IFN-γ. In this analysis, CD3 PerCP/Cy5.5 vs. CD8 BV605™ defines CD8+ vs. CD4+ (CD8-) T-cells. From those subsets, CD154 BV421™ vs. IL-2 Alexa Fluor® 700 or CD154 BV421™ vs. IFN-γ PE/Cy7 expression is compared. CD4+ cells express more CD154 and IL-2

than CD8+ cells and IFN- γ expression is similar in both populations. IL-2 is strongly co-expressed with CD154, especially in CD4+ cells. The majority of IFN- γ in CD8+ cells is singly expressed while, in CD4+ cells, the majority of IFN- γ is co-expressed with CD154, due in part to the reduced CD154 expression in CD8+ cells. However, when comparing the ratio of CD154+ cells to CD154/ IFN- γ co-expressing cells, CD154+ CD4+ and CD8+T cells are roughly similar in their ability to produce IFN- γ .



Brilliant Violet 421™, BV421™, Brilliant Violet 605™ and BV605™ are trademarks of Sirigen Group Ltd. Alexa Fluor® is a trademark of Molecular Probes, Inc.

Learn more at: biolegend.com/brilliantviolet